Relmada Therapeutics Earnings Call Highlights NDV-01 Path

Relmada Therapeutics Inc ((RLMD)) has held its Q2 earnings call. Read on for the main highlights of the call.

Relmada Therapeutics’ latest earnings call struck a cautiously optimistic tone, balancing strong clinical momentum and a fortified balance sheet against execution risk in manufacturing. Management framed the story as one of disciplined preparation: cash to fund operations into 2029, clear FDA-aligned paths for NDV-01, and engaged sites ready to enroll, but timelines now hinge squarely on CMC and contract manufacturing delivery.

Robust Cash Position Extends Runway Into 2029

Relmada closed the quarter with $217.7 million in cash, cash equivalents and short-term investments, up about 134% from $93.0 million at year-end 2025. Management said this capital should fund operations through 2029, including the full Phase III RESCUE program for NDV-01, giving investors uncommon visibility on dilution risk in a small-cap biotech.

NDV-01 Shows Striking Phase II Efficacy and Safety

Twelve-month Phase II data for NDV-01 were a central highlight, with 95% of patients achieving a complete response at any time and 76% maintaining a durable complete response at one year. Management consistently described the safety profile as favorable, positioning NDV-01 as a potentially differentiated option in a large non-muscle invasive bladder cancer market if results hold in registrational trials.

FDA Alignment and Dual Registration Pathways

The company underscored FDA alignment on two registration pathways for NDV-01, a key de-risking element for a late-stage oncology asset. Relmada plans to file the NDV-01 IND by year-end 2026 and to launch the Phase III RESCUE program promptly after clearance, aiming to convert strong mid-stage data into a viable approval strategy.

Sepranolone in Prader-Willi Moves Toward the Clinic

Beyond NDV-01, Relmada highlighted progress on sepranolone for Prader-Willi Syndrome, with formulation development now complete. The company expects to file an IND for sepranolone by year-end 2026 and initiate a Phase II proof-of-concept study once the application is cleared, targeting a rare-disease opportunity with significant unmet need.

Leadership Bench Deepened With New CBO Hire

Execution capability was another recurring theme, with Relmada appointing Bipin Dalmia as Chief Business Officer. With nearly three decades in uro-oncology and prior intravesical gene therapy launch experience, he is expected to bolster commercialization planning and partnering discussions as NDV-01 moves into registrational territory.

Clinical Infrastructure Ready With Broad Site Network

Management emphasized clinical readiness, reporting roughly 80 clinical sites engaged, split between about 60 primary and 20 backup centers. These centers are prepared to begin enrolling patients quickly once the NDV-01 IND is cleared and clinical material is in hand, potentially shortening the ramp from regulatory greenlight to active enrollment.

Tighter G&A Discipline Supports Capital Efficiency

On the cost side, general and administrative expense fell to $6.6 million from $7.4 million a year earlier, a decline of about 10.8%. The reduction was driven by lower stock-based compensation and employee costs, signaling efforts to maintain lean overhead while channeling more capital into value-driving R&D.

Per-Share Loss Improves Despite Larger Net Loss

Relmada posted a net loss of $12.9 million for the quarter, up from $9.9 million a year ago, but the loss per share narrowed to $0.11 from $0.30. The improvement in per-share results, despite higher absolute losses, reflects a larger share count and underscores how the bolstered balance sheet reshapes the optics of earnings metrics.

CMC and Manufacturing Are Key Execution Bottlenecks

The call made clear that chemistry, manufacturing and controls are now the main gating items for NDV-01. Scale-up to GMP standards, including GMP batch production and stability data with external partner Piramal, must be completed before the IND can be filed, leaving timelines vulnerable to third-party scheduling and technical execution.

IND Timeline Slips, Adding Program Uncertainty

Relmada acknowledged that IND timing for NDV-01 has shifted from a mid-2026 target to a year-end 2026 filing. This delay injects some uncertainty into the start of Phase III, and investors will be watching closely to see if CMC progress can keep the program on this revised schedule without further slippage.

R&D Spending Surges With Program Acceleration

Research and development expense climbed to $8.4 million in Q2 2026 from $2.8 million in the prior year period, a roughly 200% increase. The jump reflects higher costs tied to NDV-01 and sepranolone development, as well as rising manufacturing and drug storage expenses as the pipeline moves toward late-stage trials.

Operating Cash Burn Rises With Intensified Development

Net cash used in operating activities increased to $9.6 million from $6.4 million year over year, a 50% rise. Management linked the higher burn directly to accelerated development and manufacturing activities, signaling that investors should expect elevated cash use as Relmada pushes both key programs toward and into the clinic.

Absolute Losses Grow as Investment Phase Deepens

The company’s net loss expanded to $12.9 million from $9.9 million, an increase of just over 30%. This widening loss underlines that Relmada is firmly in an investment-heavy phase as it builds out manufacturing capabilities and prepares for costly registrational studies, even as per-share metrics trend better.

Near-Term Data Visibility Remains Limited

Investors looking for rapid clinical catalysts may need patience, as management signaled uncertainty on the timing and scope of early NDV-01 data disclosures. The team indicated that a 3-month complete response readout could slip into the first half of 2027 and suggested they prefer presenting data with a meaningful patient cohort or longer follow-up for clinical relevance.

Regulatory and Market Read-Throughs Viewed Cautiously

Relmada also pushed back on attempts to extrapolate from unrelated FDA advisory committee decisions. Management stressed that while external events highlight regulatory unpredictability, their own plans are built around direct FDA alignment for NDV-01, reinforcing a case-by-case approach rather than broad sector read-throughs.

Guidance Emphasizes 2026 INDs and Phase III Launch

Looking ahead, Relmada reiterated guidance to file INDs for NDV-01 and sepranolone by year-end 2026 and to kick off the Phase III RESCUE trial and a Phase II proof-of-concept study shortly after clearance. With the NDV-01 formulation and process locked, analytics complete, roughly 80 sites engaged, and a quick office-based dosing procedure, management believes it is structurally ready to capitalize once remaining CMC hurdles are cleared, backed by a cash position expected to support operations into 2029.

Relmada’s earnings call painted a picture of a biotech entering a decisive execution phase, underpinned by strong NDV-01 data, long cash runway and a reinforced leadership team. Yet the investment case now turns on whether the company can navigate manufacturing and regulatory milestones on its revised timeline, with investors weighing near-term delays against the potential long-term upside from a successful registrational program.